Neuromodulation : journal of the International Neuromodulation Society
-
The objectives of this study were to assess the effectiveness of cervical spinal cord stimulation in the management of intractable pain syndromes affecting the upper limb and face and to assess the reliability of a specific electrode system in this mobile environment. Forty-one patients, aged 26-76 years (median 48) with neuropathic or ischemic pain underwent the cervical epidural implantation of identical dual two-contact paddle (four contacts per system) laminectomy electrodes. Follow-up (from 5 months to 11 years, 3 months; median 4 years, 7 months) was by multiple consultations carried out by the surgeon and/or in a nurse-led specialist clinic. ⋯ Lead fracture rate was 15% of the original (11% of the total including replacements) and only 7% (5%) became dislodged. We conclude that the electrode system described provides reliable and sustained cervical cord stimulation. The outcomes are comparable with thoracic cord stimulation for neuropathic and ischemic syndromes.
-
The objective of this research was to demonstrate the potential of using peroneal nerve activity to derive timing control for stimulation in foot drop correction and to attempt recording and stimulation through the same electrode. Two subjects were implanted with cuff electrodes on the peroneal nerve. ⋯ The switching circuit successfully allowed for simultaneous recording and stimulation through the same cuff electrode. We conclude that the peroneal nerve can potentially be used to record sensory information for derivation of a stimulator control signal in a foot drop application, while at the same time being stimulated to activate foot dorsiflexors.
-
This is a retrospective study of four patients suffering from brachial plexus root avulsion of traumatic origin. Spinal cord stimulation was used to treat pain in all patients. ⋯ A stimulation trial was performed for 2 weeks and during this period the patients showed significant pain relief, so the system was permanently implanted. A significant difference of more than three points in the pain between the first and the last follow-up (0-9 months) on the Visual Analog Scale was obtained with a steady and progressive decrease of the pain scores.
-
Objective. This article presents an overview of the use of intrathecal bupivacaine (with and without opioid), focusing on laboratory data and clinical use for chronic pain. Some background on epidural use is included to support the intrathecal literature. ⋯ In addition, outcome studies are needed specifically to differentiate use of intrathecal bupivacaine based on the source and mechanism of pain. Conclusions. While there are few long-term randomized prospective studies at this point, we conclude that intrathecal bupivacaine appears to be a safe and efficacious treatment in both cancer and noncancer pain.